Burosumab in tumor-induced osteomalacia: A case report - 10/01/20
pages | 3 |
Iconographies | 3 |
Vidéos | 0 |
Autres | 0 |
Highlights |
• | Tumor-induced osteomalacia is a rare, paraneoplastic, cause of acquired osteomalacia. |
• | Treatment typically involves surgical resection of the offending tumor after localization with functional imaging. |
• | Burosumab, an anti-fibroblast growth factor-23 monoclonal antibody, is an emerging, promising treatment in those who cannot undergo surgery. |
Abstract |
Tumor-induced osteomalacia is a rare cause of acquired hypophosphatemia due to the paraneoplastic overproduction of fibroblast growth factor-23. Unlike many causes of osteomalacia, tumor-induced osteomalacia is curable by resection of the offending tumor. If a patient has a tumor that is unidentifiable, unresectable, or makes the decision to forgo surgery, medical treatment is recommended. Burosumab (KRN23) is a fully human monoclonal antibody against fibroblast growth factor-23 that was recently approved for the treatment of X-linked hypophosphatemia. We present a case of tumor-induced osteomalacia due to two somatostatin receptor avid meningiomas. The patient initially was wheelchair bound due to symptoms of diffuse bone and muscle pain with recurrent traumatic and nontraumatic fractures. Serum phosphate was 1.8mg/dL (reference range: 2.4–5.0mg/dL) with no other laboratory or historical cause. Workup revealed two widely separated intracranial meningiomas with typical magnetic resonance imaging characteristics. The duplicity of tumors precluded safe surgery and the potential delay in, or lack of, efficacy using radiosurgery prompted the treatment team to opt for medical treatment. Burosumab was initiated resulting in improvement in pain symptoms and mobility. Serum phosphate normalized. Trials are ongoing to assess the utility of burosumab in the treatment of tumor-induced osteomalacia.
Le texte complet de cet article est disponible en PDF.Keywords : Tumor-induced osteomalacia, Burosumab, Osteomalacia, Hypophosphatemia, Metabolic bone disease
Plan
Vol 87 - N° 1
P. 81-83 - janvier 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?